Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491179 | 0.87 | — | — | |
| SCHEMBL28612929 | 0.73 | CA2 (0.32) | CA2 | |
| Acetonitrile SCHEMBL5023780 | 0.71 | ACHE (0.36) | CYP3A4 | |
| SCHEMBL442673 | 0.67 | TDP2 (0.43) | HSD17B10L3MBTL1 | |
| SCHEMBL17668348 | 0.67 | MEN1 (0.30) | ATM | |
| SCHEMBL5948758 | 0.67 | MAOA (0.38) | L3MBTL1 | |
| SCHEMBL536700 | 0.67 | — | — | |
| Resorcinol SCHEMBL28632269 | 0.65 | CA12 (0.80) | CA12ALDH1A1CA2LMNACYP3A4 | |
| SCHEMBL3720965 | 0.62 | CA12 (0.33) | CA12ALDH1A1CA2LMNACYP3A4 | |
| SCHEMBL6499177 | 0.62 | ALDH1A1 (0.50) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | ADAMS JERRY LEROY | 2009-01-29 | — | — | US | disclosed |
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | disclosed |
| US-7217710-B2 | Substituted pyrazolopyrimidines | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1432714-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1432714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029209-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | DPYD, TPMT, TYMP | CA12 4511/4885ALDH1A1 512/4885CA2 4456/4885 |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | DPYD, TPMT, TYMP | CA12 4511/4885ALDH1A1 512/4885CA2 4456/4885 |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | DPYD, TYMP, TYMS | CA12 4056/4885ALDH1A1 1873/4885CA2 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.